Floatz logo

Atezolizumab

Refractory Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Refractory Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Sun Yat-sen University
Phase 3BBB
Ifosfamide
University of California, Davis
Phase 3BB
Ibrutinib
National Cancer Institute (NCI)
Phase 2BB
Carboplatin
University of California, Davis
Phase 3BB
Eloxatin
Olivia Newton-John Cancer Research Institute
Phase 3BB

View all 16 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →